Jeffrey L. Jorgensen

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-1875-2986

发表论文 356 篇 · 总被引 19371 次 · h-index 71

代表论文

• Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results (2023 · American Journal of Hematology · 被引 105)
• Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022 (2022 · MMWR Morbidity and Mortality Weekly Report · 被引 61)
• Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission (2023 · Blood · 被引 51)
• Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia (2023 · Journal of Hematology & Oncology · 被引 50)
• Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry (2022 · Cytometry Part B Clinical Cytometry · 被引 47)
• Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 −4 and higher (2022 · American Journal of Hematology · 被引 39)